REAL-WORLD STUDY OF METASTATIC MERKEL CELL CARCINOMA PATIENTS RECEIVING CHECKPOINT INHIBITORS (CPIS) VS. CHEMOTHERAPY TREATMENTS

被引：0
|
作者：
Zheng, Y. [1 ]
Kim, R. [2 ]
Yu, T. [1 ]
Dreyfus, J. [3 ]
Gayle, J. A. [3 ]
Wassel, C. L. [3 ]
Phatak, H. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Pfizer Inc, New York, NY USA
[3] Premier Inc, Charlotte, NC USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.435
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN317
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [1] Real-world outcome study among patients with renal cell carcinoma (RCC) receiving checkpoint inhibitors (CPIs).
    Phatak, Hemant
    Kim, Ruth
    Yu, Ting
    Dreyfus, Jill
    Gayle, Julie A.
    Wassel, Christina L.
    Krulewicz, Stan
    Zheng, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy
    Chandra, Sunandana
    Zheng, Ying
    Pandya, Shivani
    Yu, Ting
    Kearney, Mairead
    Wang, Li
    Kim, Ruth
    Phatak, Hemant
    FUTURE ONCOLOGY, 2020, 16 (31) : 2521 - 2536
  • [3] Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
    Cowey, C. Lance
    Mahnke, Lisa
    Espirito, Janet
    Helwig, Christoph
    Oksen, Dina
    Bharmal, Murtuza
    FUTURE ONCOLOGY, 2017, 13 (19) : 1699 - 1710
  • [4] Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
    Zhou, Fei
    Guo, Haoyue
    Zhou, Xiaolong
    Xie, Huikang
    Tian, Tian
    Zhao, Wencheng
    Gao, Guanghui
    Xiong, Anwen
    Wang, Lei
    Li, Wei
    Chen, Xiaoxia
    Zhang, Yan
    Fan, Jue
    Wu, Fengying
    Zhang, Yongchang
    Zhou, Caicun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [5] REAL-WORLD OUTCOMES IN PATIENTS WITH PENILE SQUAMOUS CELL CARCINOMA (PSCC) RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICI)
    Zhuang, Tony
    Goyal, Subir
    Brown, Jacqueline
    Carthon, Bradley
    Kucuk, Omer
    McClintock, Greta
    Yantorni, Lauren
    Bilen, Mehmet
    Master, Viraj
    Nazha, Bassel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A498 - A499
  • [6] Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
    Zheng, Ying
    Yu, Ting
    Mackey, Rachel H.
    Gayle, Julie A.
    Wassel, Christina L.
    Phatak, Hemant
    Kim, Ruth
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 213 - 226
  • [7] Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab plus axitinib vs. ipilimumab plus nivolumab
    Shah, Neil J.
    Sura, Sneha D.
    Shinde, Reshma
    Shi, Junxin
    Singhal, Puneet
    Perini, Rodolfo F.
    Motzer, Robert J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 459.e1 - 459.e8
  • [8] A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC)
    Elias, Roy
    Levonyak, Nicholas
    Christie, Alana
    Bowman, Isaac Alexander
    Kapur, Payal
    Hannan, Raquibul
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma
    Rubin, Krista M.
    Hoffner, Brianna
    Bullock, Andrea Carroll
    SEMINARS IN ONCOLOGY NURSING, 2019, 35 (05)
  • [10] Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study
    Lumlertgul, Nuttha
    Vassallo, Pietro
    Tydeman, Florence
    Lewis, Natasha
    Hobill, Abigail
    Weerapolchai, Kittisak
    Nordin, Nurul Zaynah
    Seylanova, Nina
    Martin, Luke
    Cennamo, Armando
    Wang, Yanzhong
    Rigg, Anne
    Shaunak, Nisha
    Ostermann, Marlies
    EUROPEAN JOURNAL OF CANCER, 2023, 191
12345